CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--Tau Therapeutics LLC announced today that academic collaborator Professor Roger Abounader of the University of Virginia (UVA) has been awarded a $100,000 grant from the Commonwealth Research Commercialization Fund administered by Virginia’s Center for Innovative Technology (CIT). Dr. Abounader will use Tau Therapeutics’ repositioned therapy, mibefradil, and its proprietary compound TTL-1177 for his project entitled “Therapeutic Targeting of Glioblastoma Stem Cells with Cav3.2 Blockers.” In addition to the compounds, Tau will provide expertise in support of the study.
“We are thrilled to see Dr. Abounader’s research funded through the CIT this year,” said Andrew Krouse, President and CEO of Tau Therapeutics. “His cancer stem cell research is critical to finding innovative therapies for brain cancer patients.”
Dr. Abounader’s work focuses on glioblastoma, the most common and most deadly brain tumor. Glioblastoma is resistant to both conventional chemotherapy and radiation therapy. Tau and Dr. Abounader theorize that T-type calcium channel inhibitors may overcome that resistance by sensitizing cancer stem cells to chemotherapy and radiation. Dr. Abounader will study the mechanism of action of Tau’s drugs and determine how they can best complement existing glioblastoma therapies.
Dr. Abounader’s research will generate new information on Tau’s Cav3.2 blockers, inform an ongoing Phase 1b clinical trial of Tau’s Interlaced Therapy™ in recurrent glioblastoma, and help in the design of Phase 2 clinical trials of mibefradil in cancer.
About Tau Therapeutics LLC
Tau Therapeutics, a privately held oncology company based in Charlottesville, VA, is at the forefront of cancer research focusing on controlling the proliferation pathway. Tau’s Interlaced Therapy™ is built on the rationale that using a T-type calcium channel inhibitor to increase the proportion of cancer cells and cancer stem cells at the point of maximum metabolic vulnerability in S phase will increase cell death caused by cytotoxic chemotherapies. By more effectively reducing tumor burden and killing the cells that cause recurrence, Tau believes it will offer a significant advancement in the treatment of cancer.
This press release contains forward-looking statements that are subject to risks and uncertainties, and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Tau Therapeutics LLC disclaims any intent or obligation to update forward-looking statements, except as required by law.